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The cytokine profile produced by peripheral blood mononuclear cells (PBMC) in response to leishmania
antigens and the ability of interleukin-10 (IL-10) and transforming growth factor  (TGF-) to modulate the
immune response were evaluated in 21 mucosal leishmaniasis patients. Patients with mucosal disease exhibited
increased gamma interferon (IFN-) and tumor necrosis factor alpha (TNF-) secretion and decreased IL-10
secretion compared to patients with classical cutaneous leishmaniasis. CD4 Th1 cells were the main source
of IFN- and TNF- production in mucosal leishmaniasis patients. Evaluation of cytokine gene expression in
PBMC of these patients showed that there was strong up-regulation of IFN- transcripts upon stimulation with
leishmania antigen, in contrast to the baseline levels of IL-10 mRNA. IL-10 suppressed IFN- production by
48% in cell cultures from cutaneous leishmaniasis patients and by 86% in cell cultures from healthy subjects
stimulated with purified protein derivative, whereas in similar conditions IL-10 suppressed IFN- production
by 19% in cell cultures from mucosal leishmaniasis patients stimulated with leishmania antigen. TGF-
suppressed IFN- levels to a greater extent in healthy subjects than in mucosal leishmaniasis and cutaneous
leishmaniasis patients. These data indicate that a poorly modulated T-cell response in mucosal leishmaniasis
patients leads to production of high levels of proinflammatory cytokines, such as IFN- and TNF-, as well as
a decreased ability of IL-10 and TGF- to modulate this response. These abnormalities may be the basis for
the pathological findings observed in this disease.
Leishmania spp. are obligately intracellular parasites of mac-
rophages that cause a spectrum of human diseases, including
self-healing skin lesions, diffuse cutaneous leishmaniasis, local-
ized cutaneous leishmaniasis (CL), mucosal leishmaniasis
(ML), and visceral leishmaniasis (VL) (24). In all clinical
forms, recovery and resistance to disease are dependent on
T-cell responses (11, 14). For example, VL and diffuse cuta-
neous leishmaniasis are characterized by selective anergy of
the specific cell-mediated immunity, which results in extensive
involvement of the spleen and liver in the former disease and
the skin in the latter disease, and abundant parasites are ob-
served inside macrophages (12, 14).
CL is the most common form of tegumentary leishmaniasis.
The hallmark of this illness is the development of single or
multiple ulcerated dermal lesions, which usually promptly re-
spond to antimonial therapy. A fraction (3%) of CL patients
develop mucosal disease either at the time of ulceration or
several months thereafter. ML is severely disfiguring and is
characterized by exacerbated cell-mediated immunity to the
microorganism and destructive lesions of the oral and naso-
pharyngeal cavities (13, 15). Affected individuals are often
unresponsive to standard treatment and present strong intra-
dermal skin tests and lymphocyte proliferative responses to
leishmania antigens (12, 16). On the other hand, microscopic
analysis of lesion biopsies reveals an intense inflammatory re-
action, in which lymphocytes and macrophages predominate
and few or no parasites can be found (6).
The exact pathogenic mechanism of ML has not been es-
tablished. While it has been suggested that ML may represent
a polar hypersensitivity reaction to leishmania infection (1),
other studies have revealed a mixture of type 1 and type 2
cytokines in lesions with up-regulation of mRNA for gamma
interferon (IFN-), tumor necrosis factor alpha (TNF-), in-
terleukin-4 (IL-4), and IL-10 (8, 27). Additionally, it has been
shown that lymphocytes from ML patients produce high levels
of IFN- and TNF- in response to antigenic stimulation (12,
29). These data raise the question of whether immunological
hyperactivity plays a part in ML. If it does, an exacerbated and
unmodulated immunological response may ultimately lead to
damage of host tissues. TNF- is a proinflammatory cytokine
secreted by macrophages and lymphocytes, whose production
is up-regulated by IFN- (37). A role for TNF- in the patho-
genesis of this and other chronic inflammatory parasitic and
bacterial diseases is strongly suggested by (i) increased levels of
TNF- in sera and supernatants of lymphocyte cultures (14,
29), (ii) high levels of TNF- expression in mucosal tissue (27),
(iii) decreased TNF- levels after therapy for ML (17), and (iv)
an association of TNF- levels with cerebral malaria (19) and
tissue damage following erythema nodosum leprosum (32).
In the present study, we demonstrated that an exaggerated
immune response to leishmania antigens plays a role in ML,
which is chiefly mediated by Th1-type CD4 T lymphocytes
and which is poorly modulated by the regulatory cytokines
transforming growth factor  (TGF-) and IL-10.
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MATERIALS AND METHODS
Patients. Twenty-one ML patients recruited at the health post of Corte de
Pedra, Bahia, Brazil, were enrolled in this study. The criteria for diagnosis were
a clinical picture compatible with ML, a positive delayed-type hypersensitivity
response to leishmania antigens, and parasite isolation or histopathological find-
ings characteristic of ML. All patients had a previous diagnosis of CL and were
evaluated before therapy for mucosal disease. Six patients were evaluated before
and 120 days after antimonial therapy (Glucantime; Rhodia, Sa˜o Paulo, Brazil),
at which time they were clinically cured of disease symptoms and the lesions had
become scars. In order to evaluate the immunological responses of the 21
patients with ML, we matched these individuals by age and sex with 21 patients
with cutaneous disease. Immunomodulation of antigen T-cell responses by IL-10
and TGF- was evaluated in ML patients and compared to immunomodulation
in CL patients. We also evaluated the role of these cytokines in modulating the
immune response to a different antigen. To do this, we added IL-10 and TGF-
to cultures of cells stimulated with purified protein derivative (PPD) in PPD-
skin-test-positive individuals. This research was conducted with approval of the
Ethical Committee of the Hospital Universita´rio Prof. Edgard Santos, and in-
formed consent was obtained from each participant.
Soluble leishmania antigen. The leishmania lysate (crude antigen) used for
cytokine production was prepared from a Leishmania amazonensis strain
(MHOM-BR-86 BA-125) as previously described (12). L. amazonensis was cho-
sen for antigen preparation because it is easy to grow and maintain and because
the L. amazonensis antigen produces an immune response remarkably similar to
that of Leishmania braziliensis soluble antigen. This antigen preparation was
negative for endotoxin, and it did not stimulate cells from healthy subjects who
were not exposed to leishmania infection.
Evaluation of cytokine protein and mRNA expression. Peripheral blood mono-
nuclear cells (PBMC) were separated from heparinized venous blood over a
Ficoll-Hypaque gradient (Organon Teknika, Durham, N.C.), washed, and resus-
pended in RPMI 1640 medium (Life Technologies Gibco BRL, Grand Island,
N.Y.) supplemented with 2 mM L-glutamine, 100 U of penicillin per ml, 100 g
of streptomycin per ml, and 10% heat-inactivated pooled human AB serum
(complete medium) at a concentration of 3  106 cells/ml. These cells were
plated in 24-well plates (catalog no. 3047; Falcon, Becton Dickinson, Lincoln
Park, N.J.) and either maintained unstimulated or stimulated with L. amazonen-
sis antigen (10 g/ml) or PPD (2 g/well). After incubation for 72 h at 37°C in
the presence of 5% CO2, the supernatants were collected and stored frozen until
cytokine determination. To evaluate the roles of IL-10 (DNAX Institute, Palo
Alto, Calif.) and TGF- (R&D Systems, Minneapolis, Minn.), these cytokines
were added to the cultures at concentrations ranging from 0.5 to 20 ng/ml.
To measure IFN-, TNF-, and IL-5 levels, an enzyme-linked immunosorbent
assay (ELISA) sandwich technique was used (Duo-set; Genzyme, Cambridge,
Mass., and Pharmingen, San Diego, Calif.). The IL-10 levels were measured by
using a kit obtained from R&D Systems. In order to evaluate IL-10 and IFN-
gene expression, PBMC from three ML patients were cultured in triplicate as
described above and stimulated with leishmania antigen, medium, or phytohe-
magglutinin (PHA) for 72 h. Cells were harvested, mRNA was extracted, and
reverse transcription (RT)-PCR were performed with the following primer pairs:
for IL-10, AGG GCA CCC AGT CTG AGA ACA and CGG CCT TGC TCT
TGT TTT CAC; and for IFN-, CAG CTC TGC ATC GTT TTG GGT TCT and
TGC TCT TCG ACCG TCAAA CAG CAT. Amplicons were resolved by 1%
agarose gel electrophoresis and were photographed by using a UVP apparatus
(UUP Inc., Upland, Calif.) under UV light with ethidium bromide staining.
Expression of hypoxanthine phosphoribosyltransferase was evaluated in parallel
(with primers GCG TCG TGA TTA GTG ATG ATG AAC and TGC TCT TCG
ACC TCG AAA CAG CAT) and was used for proper normalization of sample
loads in analytic runs.
Identification of cytokine-producing cells. The cellular sources of IFN- and
TNF- in ML were initially determined by cell removal assays. Specific subpopu-
lations were removed from patient PBMC by different techniques. Magnetic
separation was performed directly with PBMC by using specific MACS mi-
crobeads for enrichment of CD4, CD8, and NK cell subpopulations. To
separate NK cells, we used an NK cell isolation kit (MiniMACS; Miltenyi Biotec,
Sunnyvale, Calif.), which removed CD3, CD4, CD19, and CD33 cells. The
percentages of contamination in the populations with cells removed, as measured
by fluorescence-activated cell sorting, were as follows: population with CD4
cells removed, 0.2% CD4 cells; population with CD8 cells removed, 2%
CD8 cells; and population with NK cells removed, 1% CD56 cells.
Macrophages were removed by adherence to petri dishes (9). Briefly, 107
PBMC in RPMI 1640 medium supplemented with 10% fetal calf serum were
incubated in plastic petri dishes (10 by 15 mm; Falcon, Becton Dickinson) for 2 h
at 37°C. After a second removal step, nonadherent cells were recovered, and the
purity of the cells was determined by esterase staining (the percentages of
esterase-positive cells were 28%  3% before removal and 2%  0.7% after
removal). The enriched subpopulations were then stimulated with L. amazonen-
sis antigen as described above. Cytokines were measured by an ELISA as de-
scribed above.
To further define the specific cell types involved in TNF- production, single-
cell cytoplasmic cytokine staining was performed. PBMC were analyzed to de-
termine their intracellular cytokine expression patterns as described below and
by Sornasse et al. (36). Briefly, 1-ml cultures containing 2.5  106 PBMC were
grown in 24-well plates for 20 h with medium alone or with soluble leishmania
antigen (final concentration, 10 g/ml); a positive control containing anti-CD3/
CD28 (2 ng of anti-CD3 per ml and 1 ng of anti-CD28 per ml) was included.
During the last 4 h of incubation, Brefeldin-A (1 g/ml) was added to the
cultures, which impaired protein secretion by the Golgi complex. The cells were
then harvested by using ice-cold phosphate-buffered saline plus azide, stained for
surface markers (anti-CD4–Cychrome and anti-CD8–fluorescein isothiocyanate
[FITC] [Caltag, Burlingame, Calif.] or anti-CD14–FITC [Pharmingen]), and
fixed by using 2% formaldehyde. The fixed cells were then permeabilized with a
solution of saponin and stained for 30 min at 4°C by using anti-TNF- mono-
clonal antibody (Pharmingen) directly conjugated with phycoerythrin. FITC- and
phycoerythrin-labeled immunoglobulin control antibodies, as well as control
unstimulated PBMC, were also included in all experiments. Samples were ana-
lyzed with a FACSvantage or FACSsort (Becton Dickinson) with selection for
the lymphocyte population. In all cases, 30,000 gated events were acquired for
later analysis. This number of events was required due to the low frequency of
positive events analyzed. Controls consisting of nonstimulated versus stimulated
T-cell clones were used to standardize the antibodies used; in addition, media
alone and polyclonal antibody-stimulated (anti-CD3/CD28) PBMC were used as
positive controls.
Statistical analysis. A Mann-Whitney test was performed for all continuous,
nonparametric variables. Data were statistically significant if the probability of a
type I error was less than 0.05.
RESULTS
Profiles of cytokines secreted by PBMC from ML and CL
patients. The levels of IFN-, TNF-, IL-10, and IL-5 secreted
in vitro by PBMC from ML and CL patients revealed disease-
specific patterns (Fig. 1). The mean levels of IFN- (3,287 
2,442 pg/ml) and TNF- (1,136  1,023 pg/ml) for the 21 ML
patients evaluated were higher than the mean levels of IFN-
and TNF- observed in CL patients (1,639  1,245 pg/ml [P 
0.01] and 474  526 pg/ml [P  0.01], respectively). The IL-5
levels in ML patients were also higher (165  193 pg/ml) than
those observed in CL patients (11  18 pg/ml) (P 	 0.05). At
the same time, the levels of IL-10 in ML patients were signif-
icantly lower than those observed in CL patients (20  14 and
59  65 pg/ml, respectively [P 	 0.05]).
A comparison of the IFN- and TNF- levels measured
before and after therapy for 6 of the 21 ML patients showed
that there were unique responses for each cytokine. Whereas
there was no significant difference between the levels of IFN-
before and after antimonial treatment (2,429  653 and 2,091
 1,086 pg/ml, respectively [P  0.5]), the TNF- levels fell by
approximately 60%, from 1,092  442 pg/ml before therapy to
442  296 pg/ml after therapy (P  0.01).
Expression of IL-10 and IFN- genes was also evaluated in
PBMC cultures of three ML patients by RT-PCR (Fig. 2). All
individuals showed similar patterns of strong up-regulation of
IFN- mRNA after stimulation with leishmania antigen, com-
parable to the pattern obtained with PHA, as confirmed by
densitometry of gels. However, these patterns were not accom-
panied by corresponding increases in IL-10 gene transcription.
Densitometry showed that IL-10 mRNA kept baseline un-
stimulated levels after exposure to SLA except for patient 2,
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who was able to produce the transcript, albeit at levels that
were less than one-third (29%) of those achieved with mitogen.
Furthermore, IL-10 up-regulation following PHA stimulation
was similar to up-regulation of IFN-, confirming the ability of
the PBMC tested to express this cytokine and suggesting that
the SLA antigen preparation was a poor inducer of IL-10 in
these patients.
Cell population responsible for IFN- production in ML
patients. To determine the cellular source of IFN- synthesis
in ML patients, CD4 T cells, CD8 T cells, and NK cells were
removed from PBMC from six patients (Fig. 3). The IFN-
levels in supernatants of leishmania antigen-stimulated PBMC
were 1,773  777 pg/ml. Removal of CD4 T cells resulted in
lower IFN- levels (395  480 pg/ml) (P 	 0.005). In contrast,
the IFN- levels were not affected by removal of CD8 T cells
(1,858  813 pg/ml) and NK cells (1,547  790 pg/ml). Flow
cytometric analysis of the PBMC of four ML patients con-
firmed that CD4 T cells are responsible for more than 80% of
the IFN--producing cells following SLA stimulation (data not
shown).
Flow cytometric and cellular removal analyses to determine
the sources of TNF- in ML patients. In order to determine
the cellular sources of TNF- in ML patients, macrophages
and CD4 T cells were removed from PBMC from three
patients (Fig. 4). The TNF- levels in the supernatants of
PBMC stimulated with leishmania antigen were 1,450  89
pg/ml. Removal of macrophages and CD4 T cells resulted in
lower TNF- levels (426  376 and 182  117 pg/ml, respec-
tively), suggesting that both of these cell populations are im-
portant for production of this cytokine.
Due to the possibility that removal of macrophages could
result in decreased TNF- production caused by inefficient
antigen presentation rather than direct removal of a cytokine-
producing cell population, the cellular sources of TNF- were
FIG. 1. Cytokine profiles in ML and CL patients. IFN- and TNF- production (A) and IL-10 and IL-5 production (B) in PBMC supernatants
stimulated with leishmania antigen were determined as described in Materials and Methods. The levels of cytokines were measured by ELISA.
Symbols: , ML; Œ, CL.
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directly determined with a flow cytometer (Fig. 5). Represen-
tative contour plots for two ML patients demonstrate that
lymphocytes accounted for the majority (range for the four
patients analyzed, 60 to 90%) of the TNF--producing cells
(Fig. 5B and C), followed by CD14 monocytes (10 to 40%).
The lymphocyte-produced TNF- came primarily from CD4
T cells (average, 65%) (Fig. 5D), followed by CD8 T cells
(average, 35%) (Fig. 5E). CD14 monocytes produced vari-
able amounts of TNF- in the four patients analyzed by flow
cytometry, as shown by the comparison of the profiles for low
CD14 TNF- expression (Fig. 5B) and high (Fig. 5C) CD14
TNF- expression. However, in all cases, the frequency of
TNF--producing lymphocytes was higher than the frequency
of TNF--producing CD14 monocytes, as mentioned above.
IL-10 regulation of IFN- production in ML patients. The
role of IL-10 in the regulation of IFN- production was eval-
uated by using seven ML patients, seven CL patients, and three
healthy subjects. IL-10 was used at concentrations ranging
from 0.5 to 20 ng/ml. At low concentrations (0.5 to 2 ng/ml),
IL-10 significantly suppressed IFN- production in cell cul-
tures prepared from healthy subjects stimulated with PPD, but
FIG. 2. Cytokine mRNA expression in PBMC from three ML pa-
tients with different stimuli. A total of 3  106 PBMC were incubated
for 72 h in the presence of medium (Med), PHA, or leishmania antigen
(Ag), and then total mRNA was extracted and RT-PCR for IL-10 and
IFN- were performed to assess cytokine gene expression. Hypoxan-
thine phosphoribosyltransferase (HPRT) expression was used to nor-
malize samples and for comparison.
FIG. 3. Identification of IFN--producing cells in ML patients. As described in Materials and Methods, CD4 T cells, CD8 T cells, or NK
cells were removed from PBMC by using magnetic beads. Cultures were stimulated with leishmania antigen for 72 h and assayed for the presence
of IFN- by ELISA. The data are the means and standard deviations for six patients. The percentages of contamination in the populations with
cells removed were as follows: population with CD4 cells removed, 0.2% CD4 cells; population with CD8 cells removed, 2% CD8 cells; and
population with NK cells removed, 1% CD56 cells. An asterisk indicates that the P value is 	0.005.
FIG. 4. Identification of TNF--producing cells in ML patients. As
described in Materials and Methods, CD4 T cells or macrophages
were removed from PBMC, and the PBMC were stimulated with
leishmania antigen. TNF--producing cells were identified as de-
scribed in the legend to Fig. 3. The data are the means and standard
deviations for three patients. The percentages of contamination in the
populations with cells removed were as follows: population with CD4
cells removed, 0.2% CD4 cells; and population with CD8 cells
removed, 2% CD8 cells. The percentages of esterase-positive cells
were 28%  3% before removal and 2%  0.7% after removal.
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it had little effect on cell cultures prepared from ML and CL
patients stimulated with Leishmania antigen (data not shown).
The ability of IL-10 to down-regulate IFN- production at a
concentration of 5 ng/ml is shown in Fig. 6. The mean IFN-
levels in cell culture supernatants stimulated with leishmania
antigen (10 g/ml) were 1,641  580, and addition of IL-10 (5
ng/ml) resulted in levels of 1,330  583 pg/ml (19% suppres-
sion). These results contrast with those obtained by using
PBMC from CL patients. In CL patients, the mean IFN-
levels in cell culture supernatants stimulated with leishmania
antigen were 918  175 pg/ml. Addition of IL-10 at a concen-
tration of 5 ng/ml resulted in IFN- levels of 428  24 pg/ml
(48% suppression) (P 	 0.005). In cell culture supernatants
from healthy controls stimulated with PPD (2 g/ml), the
mean IFN- levels were 1,529  825 pg/ml, while addition of
IL-10 at a concentration of 2 ng/ml resulted in lower IFN-
levels (214 283 pg/ml; 86% suppression). The ability of IL-10
to down-regulate IFN- production in ML patient PBMC stim-
ulated with leishmania antigen was tested by using 0.5 to 20 ng
of this cytokine per ml. The maximal suppression observed was
22%. In three ML patients, IL-10 (2 ng/ml) down-regulated
IFN- production by 42% in cultures stimulated with PPD,
compared to the 86% down-regulation in the controls (data
not shown).
FIG. 5. Cell population responsible for TNF- production following antigenic stimulation. The cellular sources of TNF- production are shown
for two ML patients, as determined by using single-cell cytoplasmic staining and analysis with a flow cytometer. (A) TNF- production without
stimulus. (B and C) Frequency of CD14 monocytes which produce TNF- in two independent individuals, one exhibiting a low frequency of
TNF--producing monocytes (B) and the other exhibiting a higher frequency of TNF--producing monocytes (C) following 20 h of culture with
SLA. (D and E) TNF--producing CD4 and CD8 T cells, respectively, from another ML patient following short-term in vitro stimulation with
SLA as described in Materials and Methods. TNF-A-PE, TNF-–phosphatidylethanolamine; CD4-CYCHROM, CD4-Cychrome.
FIG. 6. Regulation of IFN- production by IL-10 in ML and CL patients. As described in Materials and Methods, PBMC from ML or CL
patients were stimulated with leishmania antigen (La Ag) in the presence or absence of IL-10. IL-10 was used at a concentration of 5 ng/ml. The
data are means and standard deviations for seven ML patients and seven CL patients. The percentage of suppression is indicated next to the single
asterisk. Two asterisks indicate that the P value is 	0.005.
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Modulation of IFN- production by TGF-. Another cyto-
kine known to inhibit IFN- production is TGF-. Therefore,
we also tested the inhibitory effects of TGF- on IFN- pro-
duction in PBMC from ML patients and CL patients stimu-
lated with leishmania antigen. Addition of TGF- (20 ng/ml)
to PBMC cultures from ML and CL patients resulted in a 15%
decrease (from 1,427  434 to 1,210  456 pg/ml) and in no
decrease (from 928  204 to 931  202 pg/ml), respectively, in
IFN- production (P 
 0.1), while it suppressed IFN- levels
up to 47% in cell cultures from healthy subjects stimulated
with PPD (from 1,490  896 to 780 343 pg/ml).
DISCUSSION
The present study showed that ML is characterized by in-
creased IFN- and TNF- production and decreased secretion
of IL-10 in response to leishmania antigens and that the
changes are accompanied by a reduced ability of IL-10 and
TGF- to down-regulate these immune responses. IFN-,
TNF-, and NO are products that are necessary to kill leish-
mania (22), but they are also implicated in the inflammation
leading to tissue damage (19, 32). Although IFN- and TNF-
represent important defense mechanisms against this parasite,
previous studies have shown that disease control and cure are
not ultimately followed by sterilization (33). This conclusion is
supported by the fact that exogenous addition of IFN- or of
T-cell products from ML patients to human macrophages in-
fected with leishmania does not eliminate the microorganism
(12, 28). Thus, overproduction of these proinflammatory cyto-
kines does not necessarily lead to parasite clearance and may
be harmful to the host, supporting our hypothesis that ML
results from an exacerbated and improperly modulated Th1
immune response to leishmania antigens. In accordance with
this reasoning, we have recently shown that the combination of
antimony with pentoxifylline, a potent inhibitor of TNF- pro-
duction (18), was able to cure ML patients who were refractory
to standard antimonial therapy (21). In light of the present
results, we suggest that the major contribution of pentoxifylline
was to decrease the inflammatory reaction responsible for the
tissue damage.
IL-10 is a major cytokine modulating immune responses in
leishmaniasis patients. We previously showed that the inability
of VL and early CL patients to produce IFN- can be restored
in vitro by neutralization of IL-10 (10, 30). Conversely, exog-
enously added IL-10 down-regulates T-cell responses in sub-
jects cured of VL (2). Our demonstration that cells of ML
patients have a decreased ability to produce and to respond to
IL-10 after stimulation with leishmania antigen suggests that
the response to this major immunoregulatory cytokine is im-
paired in ML patients. This could represent a major mecha-
nism whereby immune responses are deregulated, leading to
this severely disfiguring form of human disease.
The pathways underlying the improper production of and
response to IL-10 during ML remain elusive. One possibility is
that the concentrations of IFN- in ML patients down-regulate
the expression of IL-10R in lymphocytes and consequently
prevent IL-10 modulatory effects. IL-10 acts via a specific li-
gand (IL-10R) (23), which is structurally related to interferon
receptors (20) and might be negatively influenced by high
levels of this Th1-type cytokine. Another possibility is that the
increased secretion of other proinflammatory cytokines ob-
served in ML patients could also down-regulate IL-10R. In this
respect Michel et al. demonstrated that there is decreased
expression of the IL-10 receptor in acute exanthematic psori-
atic epidermis influenced by the proinflammatory cytokine
IL-8 (25).
TGF- is another cytokine with the ability to modulate im-
mune responses in experimental leishmaniasis, as well as in
other conditions (3, 5). For example, TGF- reduces the an-
tigen-induced cytotoxicity against K562 tumor cells by PBMC
of CL patients (4). It has also been reported that addition of
TGF- to PBMC cultures from PPD-skin-test-positive individ-
uals stimulated with PPD results in suppression of IFN- pro-
duction by 70% (26). The data presented here suggest that
along with IL-10, TGF-may play an important regulatory role
in ML patients, in which a lack of TGF-may result in the high
damaging levels of IFN- and TNF- observed.
We showed that the major source of leishmania antigen-
induced IFN- and TNF- in ML patients is CD4 Th1 cells.
These helper T lymphocytes play a central role in antigen-
specific adaptive immune responses, in contrast to the non-
antigen-specific innate NK cell response. We propose that im-
proper control of inflammatory reactions mediated by CD4
cells in ML patients may occur via anergy to and/or lack of
adequate levels of IL-10 and TGF-. A compensatory response
leading to down-regulation of the type 1 response might occur
through overproduction of Th2-type cytokines, as shown here
by the increased IL-5 observed in these patients.
We are tempted to speculate that the biased proinflamma-
tory response described here may be induced in part by selec-
tive overexpansion of T-cell clones specific for certain leish-
mania antigens. Our previous data, as well as the data of other
workers, have shown that there are distinct immune responses
to recombinant leishmania antigens, as follows: (i) gp63 in-
duces high IFN- levels and low IL-4 levels in ML patients
(31); (ii) L. braziliensis HSP83 strongly induces mRNA for
both Th1-type and Th2-type cytokines in vitro (34); (iii)
rLACK generates weak Th1-type responses but apparently
activates monocytes (7); and (iv) the elongation initiator factor
(LeIF) induces predominantly IL-12 and TNF- from PBMC
of CL and ML patients (35). In keeping with this reasoning, we
hypothesize that both host and parasite factors influence the
development of ML.
ML is a disease that is associated with a strong Th1-type
immune response to leishmania antigen, and parasites are of-
ten absent or rarely found in lesions (6). We offer evidence that
CD4 Th1-type cells are responsible for the exaggerated leish-
mania antigen-specific TNF- and IFN- production in ML
patients. This response is poorly regulated by IL-10 and
TGF-. Although Th1-type immunity protects against most
forms of leishmaniasis, our data provide evidence that inade-
quate modulation of a type 1 response may lead to an exag-
gerated reaction and may constitute the core mechanism driv-
ing the immunopathogenesis of ML.
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